Cardiovascular Diseases

29Jan 2019

Value-based pact serves up Brilinta at generic-level copays (AstraZeneca)

Anke Cardiovascular Diseases, Health Outcomes, Insurance, Medicare, Payment-Scheme, Reimbursement, USA, Value Based Contracting

FiercePharma, by Carly Helfand, Jan 28, 2019 AstraZeneca has struck a deal with UPMC Health Plan (USA) that links reimbursement for the blood thinner, which is approved to cut the risk of death or a second heart attack in people who have already had one, to patients’ cardiovascular outcomes—the usual trade-off for a value-based deal. But […]

03May 2017

Amgen refunds treatment cost with negative outcome

Anke Cardiovascular Diseases, Cost-effectiveness, Health Outcomes, Pay for performance, Pricing, Real World Data, USA, Value

FiercePharma / by Eric Sagonowsky onMay 3, 2017 On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim. Through the first-of-its-kind contract, if a patient on Repatha has a heart attack or stroke, the drugmaker will provide a full refund. As the […]